Loading company
Zenas BioPharma, Inc.
ZBIO · Nasdaq · ·
$26.74-3.0%Sep 29 close
- 1M
- -14.5%
- 6M
- +46.7%
- 1Y
- +20.5%
- 5Y
- +165.0%
ZBIO · Nasdaq · ·
$26.74-3.0%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1M | $10M | -90.00% |
| Profit | -$111.5M | -$52.2M | -113.42% |
| Profit per share | -$1.77 | -$1.25 | -41.60% |
| Free Cash Flow | -$57.2M | -$41.7M | -37.12% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Zenas BioPharma, Inc. has no earnings call transcript available.
“2026 continues to be a transformative year for Zenas, highlighted by FDA acceptance of the obexelimab BLA for the treatment of IgG4-RD, with a PDUFA date of May 27, 2027. Our expanding team is actively preparing for the potential commercialization of our first product,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Obexelimab is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. This unique inhibitory mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of the B cell lineage in chronic autoimmune disease. Obexelimab has been evaluated in eight clinical trials in a total of 383 subjects, including INDIGO. Obexelimab was well tolerated and demonstrated clinical activity across these clinical trials. Zenas expects to report topline results from a Phase 2 trial for obexelimab in systemic lupus erythematosus in the fourth quarter of 2026.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Zenas BioPharma, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.